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Background: RAS inhibitors (RASIs/ACE inhibitors & ARBs) have reduced mortality in SHF (EF<45%), but not in HFPEF (EF>45%) in randomized 
controlled trials. Since, AAs are underrepresented in these trials, whether these results are applicable to AAs with HFPEF is uncertain
Methods: All cause mortality was assessed in an AA HF quality improvement registry categorized in to SHF+RASI +ve, SHF+RASI naive, HFPEF+RASI 
+ve, HFPEF+RASI naive based on therapy (+ve) or naivety of RASIs. Survival analysis performed using Kaplan-Meier and multivariate Cox regression 
models adjusting for age, gender, NYHA class, EF, DM, HTN, hypercholesterolemia, smoking, angina, beta blockers, ACEIs, ARBs, statins, aldactone and 
bidil therapy
Results: In 594 AAs with HF 303 (51%) in SHF and 226 (38%) in HFPEF were on therapy with RASIs. In median follow up of 4.5 yrs; death occurred 
in 105 (53.0%) SHF and 67(42.1%) HFPEF. Elderly age, male gender and RASI naivety were significant predictors of mortality at multivariate level. 
RASIs therapy independently predicted survival, across the cohort (adj HR=0.6; 95%CI: 0.40-0.88; p=0.01). Further examination between SHF and 
HFPEF showed RASIs therapy in HFPEF is associated with higher survival than in SHF (adj HR=0.62; 95%CI: 0.45-0.85; p=0.003)
Conclusions: In AA patients with HF, RAS inhibition is associated with greater survival in HFPEF compared to SHF. These data suggest possible 
racial differences in response to therapy with RAS inhibitors in HFPEF. Further investigations are required.
